Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

On Thursday, Biogen Inc (BIIB) stock saw a decline, ending the day at $164.89 which represents a decrease of $-0.90 or -0.54% from the prior close of $165.79. The stock opened at $165 and touched a ...

Shares of Biogen Inc. BIIB slid 1.48% to $165.79 Wednesday, on what proved to be an all-around favorable trading session for ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

In a report released today, Robert W. Baird also maintained a Buy rating on the stock with a $300.00 price target. The company has a one-year high of $268.30 and a one-year low of $163.35. Currently, ...

With a solid Zacks Rank and top-tier Value and VGM Style Scores, BIIB should be on investors' short list. Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024.

For new and old investors, taking full advantage of the stock market and investing with ... Based in Cambridge, MA, Biogen Inc. is one of the world’s leading biotechnology companies, which ...

AIA Group Ltd raised its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 10.6% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,411 shares of the biotechnology company’s stock ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 29.8 ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...